糖精

GI(Glucose = 100)

0^*0^*

Energy(kcal/100g)

0 kcal^*0 kcal^*

Carbs(g/100g)

0 g^*0 g^*

Sugars(g/100g)

0 g^*0 g^*

功能性益處

還沒有附出處的礦物質或其他功能註記。

已引述的礦物質可在 日常最適合的甜味劑 上最多加 +2 分，見 Methods。

風險與副作用

• 高強度甜味劑

  note

  Use-level and blends matter. Packet fillers are different products. Regulatory class note — not scored.

  FDA — High-intensity sweeteners permitted for use in food (2023)

• WHO 不建議用於體重控制

  caution

  WHO 2023, conditional (low certainty): not for weight control or lowering disease risk — no long-term body-fat benefit. Not a safety ruling. Scored: the energy points it earns over sucrose are taken back on Everyday Health, Weight goals and Easy on the liver; not on Diabetic-friendly (WHO excludes people with diabetes).

  WHO — Use of non-sugar sweeteners: WHO guideline (2023)

• 兩週試驗發現葡萄糖反應受損

  note

  Cell 2022 randomized trial: saccharin impaired glucose tolerance in healthy adults (20 per arm, 2 weeks, below ADI); aspartame and stevia did not. Small and short, a lab measure rather than a disease outcome, and the sachets carried glucose. Contrary trial in Notes (Serrano 2021). Scored: glucose signal −7 on Everyday Health and Weight goals (not on Easy on the liver; synthetics are not on Diabetic-friendly).

  Suez et al. — Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance (Cell) (2022)

這不是醫療建議。若該項目會依公開公式扣分，細節列在「分數怎麼算」；分數不代表臨床嚴重程度。

註記

• Contrary trial: pure saccharin at the maximum ADI for 2 weeks (46 healthy adults, double-blind) changed neither glucose tolerance nor gut microbiota. We still score the glucose signal from Cell 2022 and print this beside it.

  Capsules without a glucose vehicle; Cell 2022 sachets carried glucose. Two short trials disagree — neither measured a disease outcome.

  Serrano et al. — High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice (Microbiome) (2021)

註記說明公開軸或風險標籤本身看不出來的事，不是醫療建議。